Diko : hydramnios

hydramnios

Nom, Nom masculin singulier, Nom masculin singulier/pluriel, Number:Sing, Number:Plur, Number:Inv, Gender:Mas, Nom masculin pluriel

Lemme

›

hydramnios

Informations lexicales

Langue:français, Langue:latin, Morpho:min, Morpho:nospace

Informations sémantiques

⊙, [polit] , source:wiki, _INFO-WORDREF-NO, _PROP-ANIME-NO, dénombrable

polarité

Forme au singulier

›

hydramnios

Variantes

›

Hydramnios

•

* Hyde (prurigo nodulaire de)

Définitions

1. Excès du volume du liquide amniotique. [Dictionnaire médical de l'Académie de Médecine]

2. (Médecine) Amnios aqueux, comportant trop d'eau.

3. L' hydramnios (aussi appelé « polyamnios », « polyhydramnios ») est un excès de liquide amniotique pendant la grossesse.

Liens externes

›

dbnary:1-hydramnios-nom

•

umls:C0020224

•

wiki:hydramnios

Associations d'idées

[F]

›

1000

•

médecine

•

maladies

•

processus pathologique

•

polyhydramnios

•

spécialités médicales

•

pathologie

•

liquide amniotique

•

excès de liquide amniotique

•

enfant de mère diabétique

•

hauteur utérine

•

exencéphalie

•

hydramnios aigu

•

hydramnios chronique

•

gynécologie-obstétrique

•

en:exposure as collected domain

•

obstétrique

•

en:immunology aspects

•

en:metabolic aspects

•

en:in cerebrospinal fluid

•

en:historical aspects qualifier

•

en:in blood

•

en:in urine

•

en:genetic aspects

•

en:taxonomic

•

maladie de Steinert

•

signe du flot

•

en:polyhydramnion

•

médecine spécialisée

•

complication de la grossesse

•

excès

•

médecine

(science)

•

maladie

•

maladie

(médecine)

•

en:prevalent in north africa

•

en:prevalent in bulgarian gypsies

•

en:prevalent in arabic, turkish, armenian, and sephardic jewish populations

•

en:prevalent among patients of asian descent, particularly japanese

•

en:prevalent among european, particularly spanish, gypsies (r1109x, 608206.0006)

•

en:prevalence ranges from 1 in 12,000 to 1 in 50,000

•

en:prevalence of sleep terrors less than 1% in adults

•

en:prevalence of sleepwalking up to 26% in childhood

•

en:prevalence of in 1 in 8,000

•

en:prevalence of essential tremor ranges from 0.4 to 6% in the general population

•

en:prevalence of 7 in 100,000 live births

•

en:prevalence of 1 in 70,000

•

en:prevalence of 1 in 6,000 to 1 in 10,000

•

en:prevalent in the old order amish in the u.s. and in finland

•

en:prevalence of 1 in 40,000 to 1 in 80,000

•

en:prevalence of 1 in 40,000

•

en:prevalence of 1 in 30,000 in northern europe

•

en:prevalence of 1 in 3,000

•

en:prevalence of 1 in 28,000 african-americans

•

en:prevalence of 1 in 227 hopi indians

•

en:prevalence of 1 in 2,833 in zimbabwe

•

en:prevalence of 1 in 150,000

•

en:prevalence of 1 in 10,000 caucasians

•

en:prevalence of 1 in 1,500

•

en:prevalence of 19 in 1,000,000 in sweden

•

en:prevalence of 0.5 to 1 in 1,000

•

en:prevalence is estimated to be 1 in 150,000

•

en:prevalent in quebec

•

en:provoked by crying or emotional upset

•

en:primary teeth affected greater than secondary teeth

•

en:prevalence in slovenia is 1 in 43,000

•

en:rapid progression to disability

•

en:rapid disease progression from ages 40 to 50 years

•

en:rapidly progressive to persistent vegetative state or death

•

en:rapidly progressive episodes

•

en:rapidly progressive deterioration (in some patients)

•

en:rapidly progressive (6-24 months)

•

en:rapidly progressive

•

en:radioresistant dna synthesis

•

en:pyridoxine responsive individuals often have milder manifestations than those not responsive

•

en:pulsatile headache lasts hours to days

•

en:psychomotor delay may already be apparent at onset of seizures

•

en:pseudomembrane formation triggered by injury, infection, irritation, surgery

•

en:protein s deficiency is found in 2-3% of patients with thromboembolism

•

en:prodromal symptoms include nasal congestion, dry throat, severe fatigue, vertigo, and headache

•

en:prominent psychiatric symptoms

•

en:progressive renal disorder

•

en:progressive neurologic deterioration if untreated

•

en:progressive disorder due to secondary myopathy

•

en:progressive disorder, usually with rapid, relentless course

•

en:progressive disease with onset in infancy

•

en:progressive deafness

•

en:progression to profound hearing loss affecting all frequencies

•

en:progression of phenotype with age

•

en:progression more frequent in men than women

•

en:progresses to involve upper limbs

•

en:prognosis good

•

en:prevalence in the finnish population of 5.8 per million

•

en:presentation after 6 months

•

en:prevalence in poland is 1 in 129,000

•

en:plantar contractures become apparent with onset of ambulation

•

en:possible x-linked dominant inheritance

•

en:possible gonadal mosaicism in one report

•

en:possible defect of a specific lipase in the pathway of free fatty acid oxidation

•

en:possible autosomal dominant form 165199 and x-linked form, cmtx5 311070

•

en:positive family history in 12-33% patients

•

en:poor response to levodopa treatment

•

en:poor response to g-csf treatment

•

en:poor response to acetylcholinesterase inhibitors

•

en:poor or no response to glucocorticoid treatment

•

en:polyps occur in teens

•

en:polg mutations account for approximately 45% of all peo cases

•

en:pneumocytosis carinii infection (12 to 42%)

•

en:pigmented spots appear in infancy through childhood and fade in adulthood

•

en:possibly x-linked recessive inheritance

•

en:physiologic decreased plasma cholinesterase activity in pregnancy, the puerperium, and newborns

•

en:phenotypic variation in severity and symptoms

•

en:phenotypic variation

•

en:zinc deficiency in breastfed offspring resolves after weaning

•

en:young adult onset

•

en:xy karyotype

•

en:x-linked mental retardation-hypotonic facies syndrome (309580) is an allelic disorder without alpha-thalassemia

•

en:worsening of symptoms during sleep

•

en:worsened by immunosuppressive therapy

•

en:worldwide incidence of 1 in 185,000 live births

•

en:worldwide frequency of 1 in 100,000 infants

•

en:women are more often affected

•

en:possible x-linked recessive inheritance

•

en:precipitated by fatigue or alcohol

•

en:prevalence in finland is 1 in 25,000

•

en:presentation in childhood includes waddling gait and knee pain/stiffness

•

en:prevalence estimated at 1 in 86,000

•

en:prevalence approximately 1 in 4,000 males

•

en:prevalence 1 in 1,250

•

en:prevalence 1-2% in northern european populations

•

en:present in jewish yemenite population

•

en:present at birth

•

en:presents with 4 types of painful episodes - (1) birth crisis, babies are born red and stiff (2) rectal crisis, triggered by defecation or emotional factors (3) ocular crisis (4) mandibular crisis, triggered by eating or yawning

•

en:presents at a later stage than sporadic wilms tumor

•

en:presents at 2 to 3 months of age

•

en:presenting symptoms in the upper body

•

en:presentation in infants - impaired growth, diarrhea, abdominal distention, vomiting

•

en:presentation in early childhood

•

en:presentation between 6-18 months

•

en:precipitated by fever

•

en:rarely reported in infants

•

en:presence of 4 major features or 3 major and 2 minor features establishes the diagnosis

•

en:prenatal or perinatal lethality in hemizygous males

•

en:prenatal or neonatal onset

•

en:prenatal onset

•

en:premature death may occur

•

en:prelingual onset in males

•

en:preferably treated with iodine supplementation rather than thyroid hormone replacement

•

en:predominantly occurs in young males with a high rate of atopic disease

•

en:precipitating factors include viral illness and pregnancy

•

en:precipitated by sleep deprivation

•

en:precipitated by infection, fasting, or intercurrent illness

•

en:rarely, patients with childhood-onset may lose the renal phosphate-wasting defect

•

en:relatively benign course

•

en:rare adult onset

•

en:see also oca1a (203100)

•

en:see also mmaa (251100)

•

en:see also hmn2b (608634)

•

en:see also distal hmn2a (158590)

•

en:see also cbld (277410)

•

en:seizures are fever-sensitive

•

en:seizures may remit with age (in some patients)

•

en:seizures may persist into adulthood

•

en:seizures may occur upon awakening or at any time during the day

•

en:seizures may be triggered by infection

•

en:seizures may be precipitated by sleep deprivation, alcohol consumption, or flashing lights

•

en:seizures easily controlled by medications

•

en:seizures are usually refractory at first

•

en:seizures are usually intractable

•

en:seizures are responsive to pyridoxine treatment

•

en:seizures are refractory to medication

•

en:seizures are provoked by immersion in hot or warm water

•

en:seizures are often refractory

•

en:seizures and dystonia peak during childhood

•

en:see the more common methemoglobinemia types i and ii (250800)

•

en:see pkd1 (601313) due to mutation in polycystin 1 (601313), pkd2 (173910) due to mutation in polycystin 2 (173910), and pkd3 (600666)

•

en:see joubert syndrome 7 (611560), an allelic disorder with a less severe phenotype

•

en:see ebn1 (121200) for an autosomal dominant form

•

en:see also x-linked edmd (310300)

•

en:rare patients with homozygous null mutations have most severe disease

•

en:regional, racial, and ethnic clustering has been noted

•

en:reported in individuals of sephardic jewish ancestry

•

en:reported in individuals of french canadian origin

•

en:reported in a large hutterite family

•

en:reported in 1 family (last curated may 2013)

•

en:repeat tracts may expand as patient ages (somatic instability)

•

en:repeat expansions range from 70 to over 1,000 (normal 5 to 30 repeats)

•

en:renal failure in second or third decade

•

en:relief is achieved by cooling or by elevating the extremities

•

en:relatively slow progression

•

en:relatively mild course

•

en:wide range of onset from childhood to adult (10 to 50 years)

•

en:relapsing-remitting course

•

en:reduced penetrance in females

•

en:residual neurologic deficits are slowly progressive

•

en:reduced penetrance (approximately 54%)

•

en:reduced penetrance (89%)

•

en:reduced penetrance, estimated to be 15% at 60 years, 21% at 70 years, and 32% at 80 years

•

en:reduced life expectancy

•

en:reduced fertility

•

en:recurrent febrile crises with lymphadenopathy, hepatosplenomegaly, vomiting, and diarrhea

•

en:recurrent cholestatic episodes in puberty, following surgery or severe trauma, and pregnancy

•

en:recurrent bacterial infections beginning in childhood

•

en:recurrent acute episodes

•

en:recurrence is possible

•

en:ratio female to male, 19:10 in index family

•

en:rare survival to teens

•

en:resembles intrauterine torch infection but without intrauterine infection

•

en:response to acetazolamide

•

en:secondary tumors develop within the skin lesions

•

en:see 609888 for a discussion on leprosy susceptibility

•

en:see 607731 for an autosomal recessive form

•

en:see 218400 for an autosomal recessive form caused by mutation in gja1 (121014.0021)

•

en:see 171060.0005 for patients with homozygous abcb4 mutations and unaffected heterozygous family members

•

en:see (608328) for a phenotypically similar autosomal dominant form

•

en:seen more frequently in infants of diabetic mothers

•

en:seasonal variation in severity of skin symptoms reported by some patients

•

en:response to zinc supplementation

•

en:scalp hair quality improves during pregnancy

•

en:sando (607459) is a phenotypic variant of autosomal recessive peo

•

en:risk of sudden death with exertion

•

en:risk of sudden death due to cardiac defects

•

en:risk of sudden death

•

en:risk of affected offspring in maternal translocation carrier - 4-10%

•

en:right side affected greater than left side

•

en:retinitis punctata albescens and macular degeneration starting in late childhood to early teens

•

en:retinal degeneration not always present

•

en:reticulate hyperpigmentation onset birth - 2 years

•

en:results in severe motor disability and loss of independent ambulation

•

en:responsive to treatment

•

en:responsive to oral mannose therapy

•

en:wide spectrum of severity

•

en:vast majority of heterozygotes are asymptomatic

•

en:wide phenotypic variability and severity

•

en:two types, type i or type a (classical cockayne syndrome, 216400) and type ii or type b (severe cockayne syndrome, 133540)

•

en:two types of platelet gpiv deficiency - type i, absence gpiv on monocytes (173510.0005) and type ii, presence gpiv on monocytes (173510.0001)

•

en:two types - one with premature ovarian failure (bpes type 1) and one without pof (bpes type 2)

•

en:two subtypes noninflammatory type a and inflammatory type b

•

en:two subtypes - seminoma and nonseminoma

•

en:two sisters have been reported (last curated september 2013)

•

en:two sisters, born of consanguineous moroccan parents, have been reported (last curated october 2014)

•

en:two sibs have been reported (last curated november 2012)

•

en:two sibs have been reported (last curated july 2013)

•

en:two sibs died before 2 years of age

•

en:two sibs, a boy and a girl, have been reported (as of july 2009)

•

en:two probands have been reported

•

en:two peaks of onset, childhood and adult

•

en:two patients with heterozygous prickle1 mutations and limited clinical and familial details have been reported (last curated january 2015)

•

en:two patients without cardiomyopathy or cataracts have been reported

•

en:two patients reported (last curated may 2013)

•

en:two patients have been reported

•

en:type b characterized by dementia, motor disturbances, and facial dyskinesia

•

en:type 3 - brandywine isolate opalescent dentin (125500)

•

en:type 2 porencephaly is usually symmetrical and results from developmental malformation

•

en:type 2n shows autosomal recessive inheritance

•

en:type 2m is characterized by decreased platelet adhesion in the presence of high molecular weight monomers

•

en:type 2b is characterized by increased affinity for platelet glycoprotein 1b

•

en:type 2: cloverleaf skull, elbow ankylosis, early demise, sporadic

•

en:type 1 - associated with osteogenesis imperfecta (125490)

•

en:two patients have been reported (as of august 2011)

•

en:two patients from 1 italian family have been reported (as of april 2010)

•

en:type iii is intermediate form

•

en:tooth agenesis ranges from 1 missing tooth to marked oligodontia

•

en:triggered by pregnancy, drugs, chemotherapy, cancer, bone marrow transplantation, infection

•

en:triggered by exercise, fasting, or other metabolic stresses

•

en:tremor is aggravated by low glucose or light

•

en:tremors develop after seizures

•

en:treatment with serine and glycine replacement may alleviate features if started at birth

•

en:treatment with oral folic acid can ameliorate, resolve, or prevent clinical symptoms and myelination defects

•

en:treatment with levodopa is not effective

•

en:treatment with folinic acid offers some benefit for anemia and seizure control

•

en:treatment with dichloroacetate (dca) prolongs survival

•

en:treatment with betaine, especially for pyridoxine nonresponders

•

en:trauma, im injection, surgery can be foci of ectopic ossification

•

en:transfusion of plasma, which has apoc-ii, causes decrease in plasma triglycerides

•

en:thromboembolism is the most common cause of death

•

en:trps2 (langer-giedion syndrome, 150230) is a microdeletion syndrome involving deletions of both trps1 (190350) and ext1 (608177) genes

•

en:three types of cystinosis are recognized

•

en:three subtypes of pfeiffer syndrome have been described - type 1: 'mild' autosomal dominant

•

en:three patients reported, one with a wdpcp mutation (last curated january 2015)

•

en:three patients have been reported (as of october 2009)

•

en:triggers are variable, even within a family

•

en:tumors are microsatellite stable

•

en:two pakistani families reported (last curated july 2014)

•

en:two families have been reported (september 2010)

•

en:two pairs of sisters described from two canadian dariusleut hutterite families (last curated september 2013)

•

en:two of 3 patients became wheelchair-bound

•

en:two main phenotypes, severe and mild

•

en:two main phenotypes, early-onset with neurologic defects and early-adult onset with gout

•

en:two loci described - eec1 (129900) and eec3 (604292)

•

en:two jordanian sibs have been reported (last curated november 2014)

•

en:two japanese families have been reported (as of february 2012)

•

en:two forms: iia (severe) and iib (mild)

•

en:two fetuses from terminated pregnancies in 1 family have been reported (last curated march 2015)

•

en:two families reported with 2 sibs each (last curated october 2012)

•

en:two families reported (last curated february 2013)

•

en:two families of french-canadian origin have been reported (last curated december 2012)

•

en:two families have been reported (last curated february 2014)

•

en:tumors usually develop between 40 and 60 years of age

•

en:two families have been reported (last curated december 2013)

•

en:two families have been reported (last curated april 2014)

•

en:two families have been reported (as of may 2012)

•

en:two families have been reported (as of march 2012)

•

en:two families have been reported (as of curation date april 2014)

•

en:two families described (last curated november 2013)

•

en:two different phenotypes exist - severe phenotype (early infantile onset, epileptic encephalopathy and often cardiomyopathy) and mild phenotype (more variable clinical presentation)

•

en:two consanguineous turkish families have been reported (as of august 2011)

•

en:two clinical presentations - solely neurologic form and a neurologic-multivisceral form

•

en:two chinese sisters and one chinese woman have been described (last curated april 2014)

•

en:two brothers have been reported (as of february 2012)

•

en:two arab muslim families have been reported (last curated october 2012)

•

en:two affected sibs have been reported (last curated july 2014)

•

en:type iiia has both liver and muscle involvement

•

en:type ii sialidosis - severe disease, dysmorphic features, variable onset (congenital or hydropic (in utero), infantile (1-12 months), juvenile (2-20 years))

•

en:wide clinical variability

•

en:variable features

•

en:variable phenotype (range from completely female to males with mild undermasculinization)

•

en:variable phenotype, some patients have very mild symptoms

•

en:variable penetrance of these features

•

en:variable penetrance

•

en:variable number of nails involved

•

en:variable neurologic phenotype

•

en:variable manifestations

•

en:variable infectious phenotype

•

en:variable heat tolerance

•

en:variable frequency and duration of episodes

•

en:variable frequency (daily to monthly)

•

en:variable features present

•

en:variable expressivity of each feature

•

en:variable phenotypic expression

•

en:variable expressivity, some patients may be clinically asymptomatic

•

en:variable expression in females otopalatodigital syndrome type i (opd1, 311300) is an allelic disorder

•

en:variable dysmorphic features

•

en:variable distribution, may be focal, segmental, multifocal, or generalized

•

en:variable degree of severity of widening and deviation of fifth fingers, both within and between affected individuals

•

en:variable clinical presentation ranging from acute onset to normal adult

•

en:variable clinical phenotype

•

en:variable cataract phenotypes within a family

•

en:variable age of onset of renal manifestations

•

en:variable age of onset (range first to third decade)

•

en:variable age of onset (range 4 to 47 years)

•

en:variable age of onset (range 1 to 30 years)

•

en:variable phenotype depending on residual enzyme activity

•

en:variable presentation and evolution of symptoms

•

en:variable age of onset (first to third decades)

•

en:very low occurrence of retinal, hepatic, pancreatic, and renal anomalies

•

en:wheelchair use at 20-30 years

•

en:wheelchair-bound after 2 decades of disease onset

•

en:waxing and waning cardiomyopathy (in some patients)

•

en:wasting of hands often occurs first

•

en:waddling gait noted at age 15-20 months

•

en:visual impairment is present at birth and is progressive

•

en:visual and hearing loss are slowly progressive

•

en:visceral multicentric involvement has a poorer prognosis than solitary lesions limited to the skin

•

en:virtually all patients with this condition are female

•

en:vhl type 2b - renal carcinoma and pheochromocytoma

•

en:vhl type 1 - renal carcinoma and hemangioblastoma

•

en:very slow progression

•

en:vertical eye movement abnormalities appear before horizontal eye movement abnormalities

•

en:variable progression

•

en:seizures remit in early childhood

•

en:variation in slc24a5 has also been associated with variation in skin color (shep4)

•

en:variably expressivity

•

en:variable survival

•

en:variable severity ranging from asymptomatic euthyroid to severe hypothyroidism

•

en:variable severity of brain malformations

•

en:variable severity (mild symptoms to severe handicap)

•

en:variable severity, some patients have a protracted course with little neurologic involvement

•

en:variable severity, ranging from 'typical' to 'severe' disease

•

en:variable severity, even within families

•

en:variable response to vitamin b12 therapy

•

en:variable response to levodopa treatment

•

en:variable response to acetazolamide and carbamazepine

•

en:variable age of onset (range 1-40 years)

•

en:variable age of onset (childhood to adulthood)

•

en:type i has most severe manifestations by age 4-5 years

•

en:usually affects children

•

en:usually sporadic, few cases described with autosomal dominant inheritance

•

en:usually sporadic

•

en:usually progressive

•

en:usually poor response to steroid treatment

•

en:usually occurs in young adulthood

•

en:usually no increased fragility of hair

•

en:usually follows a static course or is slowly progressive

•

en:usually fatal within the first few weeks of life

•

en:usually fatal in first 2 decades

•

en:usually fatal

•

en:usually clinically asymptomatic

•

en:usually a manifestation of the carney complex (cnc1, 1609890)

•

en:usher syndrome type i (congenital profound deafness, absent vestibular function, and prepubertal onset of retinitis pigmentosa) - 7 loci

•

en:usual onset before age 6 years and death by age 20

•

en:ush3 cases account for 40% of all usher patients in finland

•

en:up to 50% of patients may have various additional congenital anomalies

•

en:upper limb involvement in first decade

•

en:unusual cabbage-like odor

•

en:uncommon disorder

•

en:unbalanced chromosomal translocation carrier have thin body habitus, shallow orbital ridges, arched eyebrows, exophthalmia, ptosis, bilateral ophthalmoplegia, thin upper lip, kyphosis, pectus excavatum, and mental retardation

•

en:ultrasound detection in second trimester of pregnancy

•

en:ullrich congenital muscular dystrophy (254090) is an allelic disorder with autosomal recessive inheritance and a more severe phenotype

•

en:u.s. frequency higher in blacks than whites

•

en:typical attacks last from seconds to minutes, but longer occurrences have been reported

•

en:type i sialidosis (cherry-red spot/myoclonus syndrome ) - mild disease, no dysmorphic features, onset in second decade

•

en:type i onset at 8 to 15 months of age after normal development

•

en:usually symptomatic in adulthood with history of weakness since infancy or childhood

•

en:uterine leiomyomata are found in hereditary leiomyomatosis and renal cell cancer syndrome (150800)

•

en:variable age of onset (7-59 years)

•

en:variable age at onset (range 2 to 48 years)

•

en:variable age of onset, ranging from 11 to 50 years

•

en:variable age of onset, from 6 to 50 years of age

•

en:variable age at onset of seizures

•

en:variable age at onset (usually 20 to 30 years of age)

•

en:variable age at onset (range late infancy to adulthood)

•

en:variable age at onset (range infancy to adulthood)

•

en:variable age at onset (range from early childhood to mid-adult)

•

en:variable age at onset (range first to fourth decade)

•

en:variable age at onset (range childhood to late adult)

•

en:variable age at onset (range childhood to adult)

•

en:variable age at onset (range 8 to 60 years, mean 32)

•

en:variable age at onset (range 4 to 40 years, mostly in first or second decade)

•

en:variable age at onset (range 15 to 60 years)

•

en:variable abnormalities

•

en:variable age at onset (range 10 to 50 years)

•

en:variable age at onset (infant to adult)

•

en:variable age at onset (childhood to age 50)

•

en:variable age at onset (childhood to adult)

•

en:variable age at onset (birth to adolescence)

•

en:variable age at onset, usually in first decade, but can occur later

•

en:variable age at onset, ranging from childhood to adult

•

en:variable age at onset, range infancy to adult

•

en:variable age at onset, ranges from third to fifth decade of life

•

en:variable age at onset, mostly in third decade (range teenage years to fourth decade)

•

en:variable age at onset, from birth to ninth decade

•

en:variable age at onset, early childhood to adult

•

en:variable age at onset

•

en:seizures occur upon awakening

•

en:severe infections in untreated patients with neutropenia

•

en:seizures resolve by 4 months of age

•

en:type 2n is characterized by decreased binding affinity for factor viii

•

en:type 2cb is characterized by defective binding affinity for collagen types i and iii

•

en:type 2a is characterized by deficiency of high molecular weight monomers

•

en:type 1 porencephaly is usually unilateral and results from destructive lesions

•

en:types of psoriasis include - plaque, guttate, erythrodermic, pustular

•

en:type 3: craniosynostosis, early demise, sporadic

•

en:type 2 - hereditary opalescent dentin, not associated with bone defect (125490)

•

en:type a characterized by progressive myoclonic epilepsy

•

en:up to 25% of patients are asymptomatic or mildly affected, suggesting incomplete penetrance

•

en:usually occurs in children younger than 5 years

•

en:usually lethal in the neonatal period

•

en:usually favorable response to treatment

•

en:usually fatal in infancy

•

en:usually fatal by age 5 years

•

en:usually death in utero or rarely in neonatal period

•

en:usually begins in feet and legs (peroneal distribution), but may progress to upper limbs

•

en:usually a sporadic disorder

•

en:usually adult onset

•

en:usher syndrome type iii (postlingual progressive deafness, variable vestibular dysfunction, and progressive retinitis pigmentosa with variable age of onset) - 1 locus

•

en:user syndrome type ii (congenital moderate-severe deafness, normal vestibular dysfunction, and onset of retinitis pigmentosa in late second to early third decade) - 3 loci

•

en:up to 60% of female mutation carriers develop lobular breast cancer

•

en:upper limb involvement usually occurs later

•

en:type iia tends to have more severe phenotype with earlier onset

•

en:unusual skill with jigsaw puzzle

•

en:uncommon and rare features seen in the most severely affected patients

•

en:unaffected individuals carry 3 to 14 repeats, whereas affected individuals carry 650 to 2,500 repeats

•

en:ultrarapid metabolizers have multiple copies of the cyp2d6 gene (124030.0007)

•

en:udp-galactose-4-epimerase deficiency in circulating blood cells only ('peripheral' or 'mild' form, usually asymptomatic)

•

en:typical onset in adulthood

•

en:typically no physical features of albright hereditary osteodystrophy (aho)

•

en:type i patients have undetectable aprt activity and are homozygous or compound heterozygous for null alleles

•

en:type i is infantile-onset, severe

•

en:type ii patients are usually japanese and have significant aprt activity (10-25%)

•

en:type ii is adult-onset (kanzaki disease, 609242)

•

en:type iiib liver involvement only (15% of all cases)

•

en:usually presents in third to fourth decade (but onset can range from childhood to elderly)

•

en:two families have been reported (as of may 2011)

•

en:two loci control synthesis of c4, c4a (120810) and c4b (120820)

•

en:two japanese patients have been reported (last curated march 2013)

•

en:two japanese brothers have been reported (as of september 2011)

•

en:two fetuses have been reported (as of august 2011)

•

en:two families with different phenotypes have been reported (as of september 2010)

•

en:two families reported (last curated september 2012)

•

en:two families reported (last curated august 2014)

•

en:two families of canadian origin have been reported (last curated may 2012)

•

en:two families have been reported (last curated january 2011)

•

en:two families have been reported (last curated december 2014)

•

en:two families have been reported (last curated december 2010)

•

en:two families have been reported (as of september 2011)

•

en:two families have been reported (as of june 2011)

•

en:two main phenotypes, metabolic and neurologic

•

en:two families have been reported (as of 6/2011)

•

en:two families described (last curated july 2013)

•

en:two consanguineous turkish families have been reported (last curated january 2015)

•

en:two complementation groups - pcca (secondary to defects in the alpha chain of pcc, 232000) and pccbc (secondary to defects in the beta subunit of pcc, 232050)

•

en:two brothers have been reported (last curated august 2012)

•

en:two autosomal dominant families have been reported (as of may 2011)

•

en:two alpha-globin genes - 5-prime or alpha-2 and 3-prime or alpha-1

•

en:two-step mutation hypothesis (germline mutation followed by somatic mutation or two sequential somatic mutations)

•

en:twelve or more lesions per eye in individuals over 60 years of age

•

en:tumor predisposition syndrome

•

en:tumors may show spontaneous regression

•

en:truncating mutations in crebbp found in 10% of patients

•

en:two main groups defined by age at onset: childhood (1 to 3 years) and onset after puberty

•

en:two main presentations

•

en:two sisters have been reported (last curated february 2015)

•

en:two types - severe infantile form (type i) and milder form (type ii)

•

en:two types - lethal neonatal and less severe, late onset

•

en:two thirds of patients are female

•

en:two subtypes based on pathologic findings of 'balloon cells' - type iia, absence of balloon cells and type iib, presence of balloon cells

•

en:two subtypes, episodic (85% of patients) and chronic (15%)

•

en:two sibs have been reported (last curated october 2014)

•

en:two of 6 patients became wheelchair-bound by age 20 years

•

en:two sibs have been reported (last curated may 2013)

•

en:two sibs have been reported (as of august 2011)

•

en:two sibs born of consanguineous moroccan parents have been reported (last curated may 2012)

•

en:two presentations - rapid, fatal disorder of infancy and slowly progressive muscular disorder of childhood

•

en:two patients with point mutations in rad21 have been reported (last curated july 2012)

•

en:two patients with a wws phenotype have been reported

•

en:two patients required liver transplantation

•

en:two patients in one ashkenzai jewish family described (last curated june 2014)

•

en:two patients have been reported (as of august 2010)

•

en:two patients from spain have been reported (as of january 2012)

•

en:two pakistani families with a homozygous crybb3 mutation have been reported (last curated august 2014)

•

en:two pakistani families have been reported (last curated december 2012)

•

en:usually occurs in young adults

•

en:usually shows early age at onset (range 1 to 7 years, mean 4.6 years)

•

en:triggered by use of antibiotics (24% of cases) and nonsteroidal antiinflammatory drugs (18% of cases)

•

en:variable severity that correlates with rate and magnitude of neuronal protein accumulation

•

en:visual field and color defects invariably present only in patients with advanced loss of vision

•

en:visual acuity varies considerably, depending on the presence of secondary defects such as retinal exudates or detachment

•

en:visceral manifestations are less apparent

•

en:vhl type 2c - pheochromocytoma only

•

en:vhl type 2a - hemangioblastoma and pheochromocytoma

•

en:very variable phenotype, with some patients having many features and others only a few

•

en:very few patients reported

•

en:venous malformations previously referred to as angiomas or hemangiomas

•

en:vasculitic symptoms are associated with cold exposure (in some patients)

•

en:variant lesch-nyhan, 1.5-8% hprt activity with neurologic abnormalities, but no self-injurious behavior

•

en:variably severity

•

en:variable survival (some neonatal lethality)

•

en:variable severity of phenotype and other features may be present

•

en:waddling gait, often presenting sign in second year

•

en:variable severity and progression

•

en:variable severity (in patients with hsan2d)

•

en:variable severity, ranging from central severe to peripheral to transient

•

en:variable severity, intrafamilial

•

en:variable severity, correlates with age at onset

•

en:variable response to steroid treatment

•

en:variable response to acetylcholinesterase inhibitors

•

en:variable progression rate

•

en:variable presentation and manifestations

•

en:variable presentation

•

en:variable phenotype within families ranging from woolly hair to hypotrichosis

•

en:variable phenotype ranging from woolly to sparse hair, even within a single family

•

en:visual symptoms present by late childhood

•

en:waddling gate

•

en:variable phenotype (myotonia may or may not be present)

•

en:x-linked recessive cytochrome b-negative cgd

•

en:polyhydramnios, chronic idiopathic

•

en:polyhydramnios, megalencephaly, and symptomatic epilepsy

•

en:vesicoureteral reflux 3

•

en:cystic kidney disease with ventriculomegaly

•

en:opsismodysplasia

•

en:short-rib thoracic dysplasia 8 with or without polydactyly

•

en:thanatophoric dysplasia, type i (disorder)

•

en:chondrodysplasia, blomstrand type

•

en:disproportion in pregnancy, labor, and delivery

•

en:z allele most common, only in caucasians

•

en:young adult onset (range 13 to 50 years)

•

en:young-adult onset (18-30 years) of sensory ataxia

•

en:x-linked inheritance could not be ruled out

•

en:warm weather and alcohol are alleviating factors

•

en:worsening of hand weakness with cold (in some)

•

en:worldwide prevalence of 1/100,000

•

en:worldwide frequency of 1 in 2,000,000

•

en:women may be mildly affected

•

en:women affected more than men (3:2)

•

en:wide range of severity between affected members of the same family

•

en:wide phenotypic variation

•

en:wide phenotypic variability

•

en:wheelchair use by 10-30 years

•

en:wheelchair-bound average 12 years after onset

•

en:weakness during pregnancy in affected females

•

en:wasting of the hands is the first and most prominent manifestation

•

en:variable phenotype and severity

•

en:variable phenotype, particularly with regard to cortical malformations

•

en:usually sporadic, but 1-2% of cases are familial

•

en:variable age at onset (childhood to adulthood)

•

en:variable age at onset (range infancy to late adulthood)

•

en:variable age at onset (range infancy to 30 years)

•

en:variable age at onset (range first to third decade)

•

en:variable age at onset (range childhood to mid-sixties)

•

en:variable age at onset (range childhood to adulthood)

•

en:variable age at onset (range birth to 60 years)

•

en:variable age at onset (range 6 to 54 years)

•

en:variable age at onset (range 2 to 59 years, mean 24 years)

•

en:variable age at onset (range 25 to 78 years)

•

en:variable age at onset (range 14 to 50 years)

•

en:variable age at onset (late childhood to adult)

•

en:variable age at onset (earliest reported 7 years)

•

en:variable age at onset (birth to adult)

•

en:variable age at onset from childhood to adulthood

•

en:variable age at onset (8 to 62 years)

•

en:variable age at onset, ranging from childhood to late adulthood

•

en:variable age at onset, ranging from 18 months to 27 years

•

en:variable age at onset, range from infancy to adulthood

•

en:variable age at onset, most often in second decade

•

en:variable age at onset, infancy to adulthood

•

en:variable age at onset, first to second decades

•

en:variable age at onset, but usually in childhood

•

en:variable age at diagnosis

•

en:variability in extent of dislocation of lens and/or displacement of pupil, both within families and between eyes in a single individual

•

en:usual onset under age 30 years

•

en:usual age of onset in the 20s and 30s

•

en:variable age at onset (range teens to late adult)

•

en:variable age of onset

•

en:variable penetrance and expressivity

•

en:variable expression and severity

•

en:variable pattern of body involvement although symptoms may predominate in upper or lower body

•

en:variable neuroradiologic findings

•

en:variable manifestation of features

•

en:variable involvement of hematologic parameters

•

en:variable ictal semiology

•

en:variable frequency and severity

•

en:variable frequency (weekly to yearly)

•

en:variable frequency (2 per day up to 1 per month)

•

en:variable features and severity

•

en:variable facial dysmorphic features

•

en:variable expressivity within a family

•

en:variable expressivity in families

•

en:variable duration (minutes to hours)

•

en:variable age of onset, from early childhood to seventh decade of life

•

en:variable disease severity

•

en:variable clinical severity

•

en:variable clinical presentation

•

en:variable clinical features

•

en:variable cardiac defects

•

en:variable age of onset of parkinsonism (first decade to adulthood)

•

en:variable age of onset (range early childhood to adult)

•

en:variable age of onset (range 4 months to 45 years)

•

en:variable age of onset (range 13 to 67 years, median 48 years)

•

en:variable age of onset (infancy to 63 years)

•

en:variable age of onset (childhood to young adulthood)

•

en:variable age of onset (childhood to adult)

•

en:variable age of onset (6 to 35 years)

•

en:trp2 (langer-giedion syndrome, 150230) is a microdeletion syndrome involving deletions of both the trps1 (604386) and ext1 (608177) genes

•

en:triggered by minor head trauma

•

en:seizures tend to occur upon awakening

•

en:some patients develop diabetes mellitus as adolescents

•

en:some patients have cessation of seizures at a mean of 12 years

•

en:some patients have a secreted but biologically inactive mutant leptin

•

en:some patients have a milder nonprogressive phenotype

•

en:some patients have a contiguous gene syndrome due to loss of adjacent genes (sts, 308100 and kal1, 300836) on xp22.3 via deletions and translocations

•

en:some patients have asymptomatic hypocalcemia

•

en:some patients have additional neurologic involvement

•

en:some patients experience later reversal of hypogonadotropic hypogonadism

•

en:some patients do not show neurologic abnormalities or dysmorphic features

•

en:some patients do not manifest renal disease in the first decade of life

•

en:some patients do not have dysmorphic features

•

en:some patients do not develop stroke

•

en:some patients do not achieve independent ambulation

•

en:some patients can hold menial jobs

•

en:some patients have later onset of the disorder as young adults

•

en:some patients can attend special school

•

en:some patients become wheelchair-bound

•

en:some patients are asymptomatic and detected only by newborn screening

•

en:some mutation carriers have mild features of frontonasal dysplasia (613451)

•

en:some more severely affected patients may die in infancy

•

en:some heterozygous carriers may have mild manifestations

•

en:some heterozygotes exhibit a mild phenotype of cutaneous syndactyly between the second and third toes

•

en:some female carriers are more mildly affected

•

en:some females are affected

•

en:some features may be variable

•

en:some features are variably present

•

en:some features are variable, even within families

•

en:some patients have juvenile-onset myoclonic epilepsy

•

en:some patients have milder phenotype with later onset of symptoms, in second to third decades of life

•

en:some carrier females may manifest mild symptoms

•

en:some patients may present with adult-onset small fiber neuropathy

•

en:some patients show normal development until onset of disorder

•

en:some patients show improvement in muscle power in the teenage years

•

en:some patients show delayed development from birth

•

en:some patients respond to acetazolamide

•

en:some patients require cardiac transplantation

•

en:some patients report increased tolerance to heat

•

en:some patients present with spasticity, whereas others present with cerebellar ataxia

•

en:some patients never gain ambulation or become wheelchair-bound

•

en:some patients never achieve sitting

•

en:some patients may show neurologic improvement late in life

•

en:some patients may show a favorable response to oral coenzyme q10 supplementation

•

en:some patients may present with transient neonatal hypotonia, and then later develop classic pmc in childhood

•

en:some patients may not have recurrent infections

•

en:some patients have no manifestations

•

en:some patients may lose independent ambulation

•

en:some patients may have unilateral involvement, may be able to raise the eye above midline, or may not have ptosis--these patients are classified as having cfeom3 (cfeom3b)

•

en:some patients may have normal brain imaging

•

en:some patients may have isolated cardiac involvement

•

en:some patients may have a milder phenotype

•

en:some patients may die from cardiomyopathy in the first or second decade of life

•

en:some patients may develop concurrent failure to thrive and dyslipidemia

•

en:some patients may become wheelchair-bound

•

en:some patients have subclinical exocrine pancreatic deficiency

•

en:some patients have persistence of seizures to adulthood, but then show remission

•

en:some patients have only plantar surface involvement

•

en:some patients have only ambiguous genitalia or other evidence of disordered steroidogenesis

•

en:some families have axonal cmt (cmt2m)

•

en:some carrier females have episodes of significant hyperammonemia in infancy or childhood

•

en:some patients show rapid disease progression

•

en:severe infantile cases usually die by 6 months

•

en:signs and symptoms depend on tumor location and activity

•

en:significant number of patients are stillborn or die in neonatal period

•

en:short stepped shuffling gait

•

en:short is an acronym for short stature, hyperextensibility of joints/hernia, ocular depression, rieger anomaly, teething delay

•

en:sex ratio of 4-4.5 males to 1 female

•

en:sex ratio - 2.3 males-to-1 female

•

en:severity of skin symptoms may vary within families

•

en:severity of phenotype is not related to residual enzyme activity

•

en:severity of clinical phenotype varies both within and between kindreds

•

en:severe phenotype onset - neonate

•

en:severe neurodegenerative course resulting in a comatose state or death

•

en:severe hearing loss by age 50 years

•

en:severe epilepsy may lead to early death

•

en:severe course

•

en:severe ambulatory restriction

•

en:severe, early-onset, usually within the first days of life, with cardiomyopathy and early death

•

en:seven patients reported (as of march 2011)

•

en:seventy percent of cases are stillborn

•

en:sensory loss is rapidly progressive and severe

•

en:seizure severity and frequency tend to improve with age

•

en:seizure onset between 3 and 11 years

•

en:seizure onset after 3 months

•

en:seizures usually remit spontaneously by 12 months of age

•

en:seizures usually occur in the first months of life

•

en:simple febrile seizures usually remit by age 6 years

•

en:some affected individuals have normal subsequent development

•

en:skin lesion appear shortly after birth and tend to disappear in young adulthood

•

en:somatic mutations occur in adrenal tumor tissue (601639.0001)

•

en:smaller repeat lengths in younger generations (reverse anticipation)

•

en:slow course of functional deterioration compared to severity of mri findings

•

en:slowly progressive disease

•

en:slowly or non-progressive

•

en:slight male predominance (3:2)

•

en:slightly increased female:male ratio (1.4:1 to 2:1)

•

en:sleep disturbance or sleep apnea (obstructive, central, or mixed)

•

en:sleepwalking triggered by alcohol, sleep deprivation, stress

•

en:skin wrinkling improves with age

•

en:skin manifestation less frequently observed in cold climates

•

en:skin manifestations are more severe and of later onset than papillon-lefevre syndrome

•

en:skin lesions tend to occur on distal extremities or at elbows and knees

•

en:single mitochondrial dna deletions are found in sporadic kss patients

•

en:skin lesions manifest in the first year of life

•

en:skin lesions exacerbated by heat, exercise (sweating), and sunlight

•

en:skin lesions are fully penetrant by second decade

•

en:skin changes have onset in childhood

•

en:skin blistering and photosensitivity improve in adulthood

•

en:skin abnormalities tend to decrease with age

•

en:skewed x-inactivation in carriers

•

en:skeletal and endocrine features have not been fully characterized in all of the patients reported

•

en:size of deletion varies from cytogenetically visible deletions to undetectable cytogenetic deletions

•

en:six patients have been reported (as of october 2011)

•

en:six patients have been reported (5/18/2011)

•

en:six patients from 1 saudi arabian family have been reported (last curated december 2011)

•

en:sister of affected male siblings had mild learning disabilities and obesity

•

en:some patients show onset in childhood

•

en:some patients survive infancy

•

en:tremor may be elicited by movement or postural maintenance

•

en:thin, fine hair described in few individuals

•

en:three main phenotypes

•

en:three girls from 2 unrelated families have been reported (last curated june 2014)

•

en:three families have been reported (last curated november 2014)

•

en:three families have been reported (last curated july 2013)

•

en:three families have been reported (last curated april 2011)

•

en:three families have been reported (as of december 2011)

•

en:three families described (last curated january 2014)

•

en:three amish patients have been reported (as of february 2012)

•

en:those with larger deletions of chromosome 2q23.1 tend to have more dysmorphic features

•

en:those who survive initial acute episode have no recurrence of hepatic involvement, but may have persistent hypotonia

•

en:thoracic abnormalities tend to improve with age

•

en:this patient died at age 8 months

•

en:the relationship of central core disease to moderate multiminicore with hand involvement is unclear, for a description of classic multiminicore disease, see 602771

•

en:three patients (2 sisters and 1 unrelated female) have been reported (last curated july 2012)

•

en:the most studied group is efe pygmies from ituri forest in northeast zaire

•

en:the majority of female heterozygotes reveal ophthalmologic abnormalities - multiple, micropunctate, gray lens opacities or single, dense posterior cataract

•

en:the frequency is estimated at 1/20,000 to 1/50,000 births

•

en:the characteristic changes in the spine resolve by adolescence

•

en:there are several subtypes

•

en:tendency to lighter pigmentation than unaffected relatives

•

en:teeth may undergo post-eruptive changes

•

en:systemic iron overload due to ineffective erythropoiesis

•

en:systemic amyloid deposition may occur

•

en:symptom onset at birth or infancy arnold-chiari type ii is uniquely associated with myelomeninogocele (182940)

•

en:symptoms vary from asymptomatic patients to patients with metabolic acidosis

•

en:symptoms usually resolve without treatment

•

en:three males in 1 family have been reported (last curated august 2012)

•

en:three patients from 1 mexican family has been reported (last curated april 2013)

•

en:symptoms usually induced only by strenuous exercise

•

en:tremor is aggravated by emotional stress

•

en:treatment with vitamin d and phosphate is effective

•

en:treatment with polyethylene glycol-modified bovine ada, bone marrow transplantation, and/or gene therapy

•

en:treatment with oral coenzyme q may ameliorate symptoms

•

en:treatment with hematopoietic stem cell transplant if diagnosed at < 24 months of age

•

en:treatment with enzyme replacement therapy

•

en:treatment with bh4 is effective

•

en:trauma may accelerate symptoms

•

en:trauma, anxiety, and/or stress can precipitate or aggravate edema

•

en:torso and upper body remain normal in shape and contour

•

en:thrombosis triggered by pregnancy, oral contraceptives, trauma, surgery

•

en:three variants distinguished by age of onset - infantile ( onset before age 2), juvenile (onset in childhood), and adult

•

en:three patients have been described (last curated january 2013)

•

en:three types of pct: type i (176090) sporadic, presents in adults: types ii and iii (176100) familial, presents in childhood

•

en:three times more common in males

•

en:three stages of disease progression - stage 1 (subclinical), stage 2 (early myoclonic), stage 3 (disabling myoclonic)

•

en:three patients in one family have been reported (as of october 2011), and only one mutation carrier exhibited mental retardation and ataxia

•

en:three patients have been reported (as of november 2010)

•

en:three patients have been reported (as of august 2011)

•

en:symptoms usually manifest in childhood including waddling gait and painful, stiff joints

•

en:symptoms typically begin in childhood

•

en:some patients with advanced loss of vision have normal eog

•

en:spots occur in 95% of patients but can be absent

•

en:sudden death due to cardiac arrhythmia may occur

•

en:sudden cardiac death in some families

•

en:successful treatment with oral isotretinoin

•

en:subtype 3c (231005) comprises cardiovascular calcifications

•

en:subtype 3a comprises myoclonus and dementia

•

en:subtle facial phenotype compared to other types of hpe

•

en:subset of patients have leigh syndrome (256000)

•

en:subset of patients have cytochrome c oxidase deficiency (see 220110)

•

en:striking intrafamilial variability

•

en:static or slowly progressive

•

en:stage iv, late motor deterioration (when ambulation ceases)

•

en:stage ii, rapid developmental regression (onset 1-4 years)

•

en:sporadic occurrence is associated with advanced paternal age

•

en:sudden death secondary to impaction of medulla oblongata

•

en:sporadic cases often single lesions versus multiple lesions in familial cases

•

en:spontaneous reversal of gnrh deficiency may occur in some patients

•

en:spontaneous resolution usually after 12 months of age

•

en:spontaneous resolution by 12 months of age with no recurrence later in life

•

en:spontaneous bleeding is rare

•

en:spinal tumors are necessary for diagnosis

•

en:spectrum of malformations resulting from impaired midline cleavage of the embryonic forebrain

•

en:spasticity occurs before parkinsonism

•

en:sparing of some nails in some individuals

•

en:some phenotypic overlap with rett syndrome (312750)

•

en:some pedigrees are consistent with autosomal dominant inheritance

•

en:some patients with onset of severe disease in infancy are diagnosed with leber congenital amaurosis, whereas other patients with childhood onset of less severe retinal dystrophy are diagnosed with retinitis pigmentosa

•

en:sudden death in affected females occurs in the forties

•

en:sudden infantile death may occur

•

en:symptoms show insidious onset in the late first through third decades

•

en:symptoms may be aggravated by acute illness

•

en:symptoms remain focal

•

en:symptoms relieved by progesterone antagonist (in some patients)

•

en:symptoms progress with worsening myopathy

•

en:symptoms precipitated by sudden movement, stress, exertion, fatigue, illness

•

en:symptoms precipitated by sudden movement, stress, exertion, fatigue

•

en:symptoms precipitated by stress, exertion, fatigue, alcohol

•

en:symptoms precipitated by alcohol, caffeine, fatigue, stress, exertion, ovulation, menstruation

•

en:symptoms often improve gradually with age

•

en:symptoms occur only during sleep

•

en:symptoms noted at 2-3 years

•

en:symptoms may decrease after age 30 years

•

en:symptoms may be exacerbated in women during pregnancy or by oral contraceptives (see 614972)

•

en:symptoms improve following sleep

•

en:surgical intervention is not always curative

•

en:symptoms highly variable - rapidly progressive course leading to hepatic failure versus acute hepatic crisis

•

en:symptoms can be prevented by strict dietary restriction

•

en:symptoms begin focally, later segmental or generalized

•

en:symptoms are often responsive to alcohol

•

en:symptoms are aggravated by febrile illness

•

en:symptoms aggravated by fatigue, exertion, sleep deprivation, emotion, hunger

•

en:swelling starts to fade by age 30 years and gradually becomes unremarkable

•

en:susceptibility to infections starts in the first week of life

•

en:survivors have mental retardation, spasticity, and adducted thumbs (masa syndrome findings (303350))

•

en:surviving infants develop severe nonbullous ichthyosiform erythroderma

•

en:survival to 5-15 years of age

•

en:survival to 20s-60s in iib

•

en:survival past infancy is rare

•

en:three patients have been reported (as of february 2012)

◀

totaki

›

surveillance

•

diagnostic

•

maternité

•

santé

•

complications

•

échographie

•

grossesse

•

foetus

•

liquide

wikipédia

[F]

›

syndrome de Bartter

•

DOI

•

grossesse

•

malformation

•

Grand dictionnaire terminologique

•

Grossesse

•

International Standard Serial Number

•

ISSN

•

PubMed

•

PMID

•

PubMed Central

•

PMCID

•

syphilis

•

Malformation

•

Liquide amniotique

•

Digital Object Identifier

•

Sac amniotique

•

sac amniotique

•

Parvovirus B19

•

parvovirus B19

•

Toxoplasmose

•

toxoplasmose

•

Syphilis

•

liquide amniotique

Thèmes/domaines

›

médecine

•

maladies

•

en:tictology

•

pathologie

•

spécialités médicales

•

gynécologie-obstétrique

•

en:obstetrics

•

médecine spécialisée

•

tocologie

•

obstétrique

•

en:maieutics

•

médecine

(science)

•

en:midwifery

•

maladie

•

en:specialized branches of medicine

•

en:obstetrical

•

Spécialités médicales

•

en:obstetric

•

en:tocology

•

Médecine

•

biologie

•

chimie

•

chimie organique

•

biochimie

•

en:technique

•

chymie

•

en:organic chemistry

Synonymes et quasi-synonymes

›

polyhydramnios

•

Hyde (prurigo nodulaire de)

•

en:polyhydramnios

•

polyglucosanes (neuropathie à )

•

glucide

•

hydrargirose

•

hydranencéphalie

•

hydramnios chronique

•

en:hydranencephaly

•

intoxication mercurielle

•

carbohydrate

•

hydratase

•

en:hydrargyrism

•

en:hydrocarbon

•

hydrocarbon

•

en:carbohydrate

•

hydrargyrisme

•

hydramnios aigu

•

hydratation cutanée

•

hydroadénome

•

hydrate de carbone

•

hydrargyrie

•

en:hydrargyria

•

hydrocarbure

•

hydrocalice

•

hydrocarboné

•

hydroa vacciniforme de Bazin

•

hydroa aestivalis

•

hydroa

•

hydrine

•

hydrencéphalocèle

•

hydrencéphalie

•

or noir

•

carburant

(Nom)

•

pétrole

(Nom)

•

en:benzene

•

carburant

•

pétrole

•

mercurialisme

•

Or noir

•

hydrocarbone

•

benzène

•

hydrargyrose

•

effet toxique du mercure et ses composés

•

intoxication par le mercure

•

en:hydratase

Traduction de hydramnios

›

en:polyhydramnios

•

en:hydramnion

•

en:polyhydramnion

Génériques

[F] [H]

›

complication de la grossesse

•

facteur de risque

•

excès

•

complication

(médecine)

•

maladie

(médecine)

•

excès de liquide amniotique

•

processus pathologique

•

Hyde

•

molécule

•

maladie

•

processus

•

intoxication

•

en:organic compound

•

produit

•

pathologie

•

hydroa

•

composé organique

•

produit chimique organique

•

produit chimique

•

composé chimique organique

•

en:chemical

•

en:organic chemical

•

composé chimique

•

en:chemical compound

Spécifiques

›

50+

hydramnios aigu

•

avec accouchement, polyhydramnios

•

hydrocarbure

•

Hyde (prurigo nodulaire de)

•

hydramnios chronique

•

en:acute polyhydramnios

•

hydramnios affectant le foetus ou le nouveau-né

•

polyhydramnios avec accouchement

•

en:polyhydramnios with delivery

•

hydrocarbure léger

•

benzopyrène

•

norbornylène

•

hopane

•

C30H48

•

hydrocarbure de roche-mère

•

cyclopropène

•

methane

•

naphtaline

•

éthylène

•

HAP

•

stilbène

•

indane

•

en:pentane

•

œstrane

•

squalène

•

isoprène

•

en:2-bromopropane

•

hydrocarbure aliphatique insaturé

•

en:cyclohexane

•

en:hopane

•

méthane

•

isobutane

•

propylène

•

en:alkenes

•

en:naphtha

•

en:coal oil

•

en:lamp oil

•

décane

•

propane

•

en:petrol

•

en:gasohol

•

en:gas

•

pyrazole

•

en:docosane

•

hectane

•

cyclohexène

•

chrysène

•

fluoranthène

•

triacontane

•

tétracosane

▶

Termes dérivés morphologiquement

›

amnios

Locutions/termes composés

›

oligo-hydramnios

•

foetus et nouveau-né affectés par un hydramnios

•

foetus ou nouveau-né affecté par un hydramnios

•

hydramnios chronique

•

foetus ou nouveau-né affecté par un hydramnios aigu

•

hydramnios aigu affectant le foetus ou le nouveau-né

•

foetus ou nouveau-né affecté par un hydramnios chronique

•

hydramnios affectant le foetus ou le nouveau-né

•

hydramnios chronique affectant le foetus ou le nouveau-né

•

hydramnios aigu

Caractéristiques de hydramnios

›

•

liquide

(fluide)

Lieux où peut se trouver/dérouler hydramnios

›

cavité amniotique

•

pipeline

•

plage polluée

•

pipeline

(conduite)

•

réservoir

(véhicule)

Que peut-on faire à/de hydramnios ? (patient)

›

importer

(commerce)

Causes associées à hydramnios

›

diabète maternel

•

Diabète maternel

•

atrésie choanale

•

en:fetal malformation

•

malformation foetale

•

diabète

•

atrésie des choanes

•

en:placental anomaly

•

en:maternal disease

•

en:choanal atresia

Conséquences associées à hydramnios

›

en:premature delivery

•

en:premature birth

•

naissance avant terme

•

accouchement prématuré

•

en:preterm delivery

•

dermite de contact

•

dermatite de contact

•

eczéma aigu

•

en:contact dermatitis

•

omotocie

Sentiments/émotions associés à hydramnios

›

angoisse

•

inquiétude

•

terreur

•

peur

•

méfiance

•

crainte

•

anxiété

•

frustration

•

dégoût

•

tristesse

•

haine

•

colère

•

mal-être

•

en:fearing

•

surprise

•

indifférence

•

en:trepidation

•

en:free floating anxiety

•

* trouble anxieux généralisé

• Mathieu Lafourcade • LIRMM (données libres en Creative Commons) •

• This page link : https://www.jeuxdemots.org/diko.php?gotermid=96504 • caches: c1=52 c2=1215 c3=1

♥

po

la

ti

le

as

ku

co

lo

to

ta

ta

xe

po

li

?!

!?

[Vider le cache]